We include captopril in CUSP9* based on three not necessarily discrete lines of evidence: a] data showing that captopril inhibits activity of soluble matrix metalloproteinase (MMP) -2 and MMP-9, with a parallel data set showing these MMPs to be a growth facilitating factor in glioblastoma growth, b] ACE inhibitors, including specifically captopril have been shown to inhibit angiogenesis, both normal and cancer-related, c] empirical studies showing growth inhibition in cancer models. This evidence concerns the gene ACE and glioblastoma.